Conatus Pharmaceuticals (NASDAQ:CNAT)

CAPS Rating: 4 out of 5

Results 1 - 9 of 9

Recs

0
Member Avatar pchop12316 (77.40) Submitted: 7/6/2015 10:59:37 AM : Outperform Start Price: $5.08 CNAT Score: -4.73

Do not like it, but it will probably go up in price

Recs

3
Member Avatar zzlangerhans (99.66) Submitted: 7/3/2015 5:21:44 PM : Outperform Start Price: $5.13 CNAT Score: -5.48

Conatus clearly belongs to that cadre of NASH stocks that the market has decided not to take very seriously, probably wisely. Lead drug emricasan was dumped by Pfizer and acquired by Conatus on the cheap. A phase II trial of emricasan for NASH failed to impress due to the low bar of success that the company used for a primary endpoint. However, the stock is cheap with a market cap of 100M and has shown sparks of vitality in the past. Positive feedback from the FDA regarding plans for registrational trials of emricasan in NASH could lead to a spike later this year, as long as the macro environment or a sector-wide pullback doesn't create too much erosion in the near term.

Recs

0
Member Avatar km00nster (< 20) Submitted: 3/26/2015 3:05:36 PM : Outperform Start Price: $6.89 CNAT Score: -31.20

Excellent news today! Should hit 12 dollars by the end of the year.

Recs

0
Member Avatar joienpaix (24.91) Submitted: 3/13/2015 4:39:05 PM : Outperform Start Price: $5.69 CNAT Score: -15.32

jeepdrew2 TP 8

Recs

0
Member Avatar drugtrader (95.08) Submitted: 3/6/2015 7:08:50 PM : Outperform Start Price: $6.02 CNAT Score: -19.12

Perhaps it will go up 50 or 100% in 1 day again...as it seems to do from time to time.

Recs

1
Member Avatar OKwarrior (41.26) Submitted: 11/9/2014 5:37:27 PM : Outperform Start Price: $6.89 CNAT Score: -32.08

small biopharma company specializing in development of drugs for liver disease (think Gilead). They have ongoing trials for 5 different diseases, NASH, acute on chronic liver failure, portal hypertension, post transplant liver fibrosis w. clearance of Hep C

Recs

0
Member Avatar aki92656 (74.83) Submitted: 3/31/2014 4:10:53 PM : Outperform Start Price: $8.05 CNAT Score: -51.62

20140331 started at 8.20

Recs

0
Member Avatar usubanas (99.76) Submitted: 3/25/2014 3:29:16 PM : Outperform Start Price: $9.35 CNAT Score: -60.42

Phase 2 NAFLD/NASH trial results expected 2nd half 2014. At 145M, great risk reward.

Recs

1
Member Avatar sinvestor (55.86) Submitted: 1/14/2014 6:36:43 AM : Underperform Start Price: $12.16 CNAT Score: +75.09

Really???

Results 1 - 9 of 9

Featured Broker Partners


Advertisement